<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909649</url>
  </required_header>
  <id_info>
    <org_study_id>seroma in breast surgery</org_study_id>
    <nct_id>NCT00909649</nct_id>
  </id_info>
  <brief_title>Influence of Fibrin Glue on Seroma Formation After Modified Radical Mastectomy</brief_title>
  <acronym>MRM</acronym>
  <official_title>Influence of Fibrin Glue on Seroma Formation After Modified Radical</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was carried out from January 2005 to December 2007 at Mansoura university
      hospital. Fifty patients who had breast cancer were included in the study, MRM was done for
      all patients. Patients were randomly divided into two groups. Group І with fibrin glue 4ml of
      fibrin glue was sprayed on the surgical area with Y canula and group П without fibrin glue.
      Preoperative, Operative and Postoperative data were collected including postoperative
      measurement of drainage, date of removal of the drain, state of the wound, incidence of
      Seroma formation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was carried out from January 2005 to December 2007 at Mansoura university
      hospital, Departement 8 of surgical department. This study approved by local ethical
      committee Fifty patients had breast cancer were included in the study. Patients who received
      preoperative chemotherapy and radiotherapy were exclude Also, patients with previous axillary
      surgery or patients who underwent simultaneous reconstructive surgery and breast conservative
      surgery and locally advanced breast cancer were exclude.

      Informed written consent was obtained from all patients included in the study. All patients
      include in the study, MRM was done for then and axillary lymphadenectomy extended to the
      axillary level III was done with sharp dissection and ligation of the visible lymph vessels
      and minor blood vessel. After performing hemostasis in the mastectomy and axillary area.
      .Patients were randomly divided by closed envelop into two groups. Patients were randomized
      at end of surgical procedure to avoid possible treatment bias during surgical procedure.

      Group І (with fibrin glue) and group П without fibrin glue. In fibrin glue group. 4 ml of
      fibrin glue was sprayed on the surgical area with Y canula (doubleject application system).
      In group 11 after good haemostasis the same sized drain was applied in axillary and breast
      area and incision was closed. Followed by external compression for 10 minutes in both groups.
      Drains were left in places until the drainage for the preceding 24 h was less than 30 ml/day.

      Data collected Preoperative data collected included age, body mass indexed (BMI), medical and
      surgical history, history of chemotherapy, radiotherapy Operative data included estimated
      blood loss, types of dissection, duration of the operation Postoperative data included
      hospital stay , postoperative measurement of drainage daily , date of removal , state of the
      wound ( infection , haematoma, necrosis , opened wound ), number of axillary lymph nodes
      dissected , cancer stage , number of axillary lymph nodes positive, incidence of Seroma
      formation , interval of Seroma resolution , Seroma aspirated volume and number of
      postoperative visits Seroma formation was defined as inability to remove participant drain by
      postoperative day 10 because of high output (more than 30 ml /day drain Seroma) and / or the
      need to aspirate of fluid after removal of the drain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroma Formation</measure>
    <time_frame>within 30 days postoperative</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1 fibrin glue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 ml of fibrin glue was sprayed on the surgical area with Y canula ( doubleject application system).One milliliter of fibrin glue contains 70-100 mg. fibrinogen, 10-50 u factor 8 aprotinin 3000k iu/ml, 2-9 mg fibronectin,40-120 ug plasminogen ,4 Iu/ml thrombin, 40 mmol cocl2/L (immuno AG/austrial)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 non fibrin glue</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>after good haemostasis the same sized drain was applied in axillary and breast area and incision was closed. Followed by external compression for 10 minutes in both groups. Drains were left in places until the drainage for the preceding 24 h was less than 20 ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fibrin glue in breast surgery</intervention_name>
    <description>fibrin glue 8 ml in the bed after modified radical mastectomy in fibrin treated group</description>
    <arm_group_label>1 fibrin glue</arm_group_label>
    <other_name>fibrin glue after modifed radical mastectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with operable breast cancer

        Exclusion Criteria:

          -  Patients who received preoperative chemotherapy and radiotherapy were exclude

          -  Patients with previous axillary surgery

          -  Patients who underwent simultaneous reconstructive surgery and breast conservative
             surgery

          -  Locally advanced breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ayman elnakeeb</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ayman Elnakeeb</name>
      <address>
        <city>Mansoura , Egypt</city>
        <state>Mansoura,egypt</state>
        <zip>050</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ayman Elnakeeb</name>
      <address>
        <city>Mansoura</city>
        <zip>050</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Ulusoy AN, Polat C, Alvur M, Kandemir B, Bulut F. Effect of fibrin glue on lymphatic drainage and on drain removal time after modified radical mastectomy: a prospective randomized study. Breast J. 2003 Sep-Oct;9(5):393-6.</citation>
    <PMID>12968960</PMID>
  </reference>
  <results_reference>
    <citation>Johnson L, Cusick TE, Helmer SD, Osland JS. Influence of fibrin glue on seroma formation after breast surgery. Am J Surg. 2005 Mar;189(3):319-23.</citation>
    <PMID>15792759</PMID>
  </results_reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2009</study_first_posted>
  <results_first_submitted>December 5, 2008</results_first_submitted>
  <results_first_submitted_qc>May 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2009</results_first_posted>
  <last_update_submitted>May 27, 2009</last_update_submitted>
  <last_update_submitted_qc>May 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>mansoura university hospital</name_title>
    <organization>mansoura university,egypt</organization>
  </responsible_party>
  <keyword>fibrin glue</keyword>
  <keyword>seroma</keyword>
  <keyword>mastectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>medical clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fibrin Group</title>
        </group>
        <group group_id="P2">
          <title>Non Fibrin Group</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fibrin Group</title>
        </group>
        <group group_id="B2">
          <title>Non Fibrin Group</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="11.5"/>
                    <measurement group_id="B2" value="51.6" spread="10.8"/>
                    <measurement group_id="B3" value="51.9" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroma Formation</title>
        <description>the mean total drainage volume</description>
        <time_frame>within 30 days postoperative</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrin Group</title>
          </group>
          <group group_id="O2">
            <title>Non Fibrin Group</title>
          </group>
        </group_list>
        <measure>
          <title>Seroma Formation</title>
          <description>the mean total drainage volume</description>
          <population>ITT</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="770.48" spread="70.81"/>
                    <measurement group_id="O2" value="1089.51" spread="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elnakeeb Ayman</name_or_title>
      <organization>Mansoura university hospital</organization>
      <phone>0106752021</phone>
      <email>elnakeebayman@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

